Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.
Pediatr Nephrol
; 36(9): 2891-2894, 2021 09.
Article
em En
| MEDLINE
| ID: mdl-34002291
ABSTRACT
BACKGROUND:
Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies.METHODS:
The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS.RESULTS:
A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects.CONCLUSIONS:
If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Escherichia coli
/
Escherichia coli Shiga Toxigênica
/
Síndrome Hemolítico-Urêmica
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article